Zasocitinib

Generic Name: Zasocitinib

Clinical Trials

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

Phase 3

Not yet recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Zasocitinib
Drug: Deucravacitinib
Drug: Placebo to match zasocitinib
Drug: Placebo to match deucravacitinib

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT06973291

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Zasocitinib
Drug: COC
Drug: Metformin
Drug: Digoxin
Drug: Esomeprazole

First Posted Date: 2025-01-27

Last Posted Date: 2025-04-04

Lead Sponsor: Takeda

Target Recruit Count: 78

Registration Number: NCT06793943

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

Phase 2

Not yet recruiting

Conditions: Crohn's Disease
Ulcerative Colitis

Interventions: Drug: Zasocitinib

First Posted Date: 2025-01-08

Last Posted Date: 2025-05-07

Lead Sponsor: Takeda

Target Recruit Count: 183

Registration Number: NCT06764615

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Phase 3

Recruiting

Conditions: Psoriatic Arthritis

Interventions: Drug: Zasocitinib
Drug: Placebo

First Posted Date: 2024-11-04

Last Posted Date: 2025-04-17

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT06671496

Locations: 🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ, Tucson, Arizona, United States
🇺🇸
Biovin Enterprises LLC dba Medvin Clinical Research | Covina, CA, Covina, California, United States
🇺🇸
Direct Helpers Medical Center, Hialeah, Florida, United States

and more 118 locations

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3

Recruiting

Conditions: Psoriatic Arthritis

Interventions: Drug: Zasocitinib
Drug: Active Comparator
Drug: Placebo

First Posted Date: 2024-11-04

Last Posted Date: 2025-05-04

Lead Sponsor: Takeda

Target Recruit Count: 1088

Registration Number: NCT06671483

Locations: 🇵🇱
FutureMeds Wroclaw, Wrocław, Poland
🇺🇸
AARR- Chandler AZ, Chandler, Arizona, United States
🇺🇸
Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ, Phoenix, Arizona, United States

and more 193 locations

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: TAK-279

First Posted Date: 2024-08-12

Last Posted Date: 2025-04-17

Lead Sponsor: Takeda

Target Recruit Count: 1300

Registration Number: NCT06550076

Locations: 🇺🇸
Total Dermatology, Birmingham, Alabama, United States
🇺🇸
University of Alabama Hospital - Whitaker Clinic -, Birmingham, Alabama, United States
🇺🇸
Cahaba Dermatology Skin Health Center, Hoover, Alabama, United States

and more 269 locations

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Phase 3

Recruiting

Conditions: Generalized Pustular Psoriasis
Erythrodermic Psoriasis

Interventions: Drug: TAK-279

First Posted Date: 2024-03-21

Last Posted Date: 2025-01-10

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06323356

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵
Fujita Health University Hospital, Toyoake, Aichi, Japan
🇯🇵
Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan

and more 17 locations

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Repaglinide
Drug: Midazolam
Drug: TAK-279

First Posted Date: 2024-03-04

Last Posted Date: 2024-05-23

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06290050

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-279
Drug: TAK-279 Placebo
Drug: Moxifloxacin
Drug: Moxifloxacin Placebo

First Posted Date: 2024-02-14

Last Posted Date: 2024-07-11

Lead Sponsor: Takeda

Target Recruit Count: 120

Registration Number: NCT06258265

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Phase 2

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: TAK-279
Drug: Placebo

First Posted Date: 2024-02-12

Last Posted Date: 2025-05-16

Lead Sponsor: Takeda

Target Recruit Count: 207

Registration Number: NCT06254950

Locations: 🇺🇸
GastroIntestinal BioSciences, Los Angeles, California, United States
🇺🇸
United Medical Doctors, Murrieta, California, United States
🇺🇸
UCI Health, Orange, California, United States

and more 173 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy